Aerie Pharmaceuticals Inc. (AERI) Fundamentals

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.
SHARE INFORMATION
Market Cap$ 753,615,457
Shares Outstanding49,417,407
Float48,570,349
Percent Float98.29%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 194,134,000
Latest Fiscal EPS$ -1.62
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions384
Institutional Holdings Date2022-10-31
Institutional Bought Previous 3 Months4,782,017
Institutional Holdings Percent132.8%
Institutional Sold Previous 3 Months11,346,691
Insider Holdings Date2022-10-31
Insider Bought Previous 3 Months-
Insider Holdings Percent3.1
Insider Sold Previous 3 Months1,036
Insider Shares Owned1,547,148
TRADING INFO
52 Week High$ 15.37
52 Week Low$ 4.81
52 Week High Change$ 47.20
21 Day Moving Average$ 15.2395
21 Day Extended Moving Average$ 15.2328
50 Day Moving Average$ 15.205
50 Day Extended Moving Average$ 14.8573
200 Day Moving Average$ 10.4885
200 Day Extended Moving Average$ 12.1473
10 Day Average Volume121,518
20 Day Average Volume286,643
30 Day Average Volume362,501
50 Day Average Volume584,163
Alpha-0.004994
Beta-0.0650
Standard Deviation0.215628
R20.000257
7 Day Price Change$ 0.00
7 Day Percent Change0.0%
21 Day Price Change$ 0.02
21 Day Percent Change0.13%
30 Day Price Change$ 0.04
30 Day Percent Change0.26%
Month to Date Price Change$ 0.00
Month to Date Percent Change0.0%
Quarter to Date Price Change$ 0.12
Quarter to Date Percent Change0.79%
180 Day Price Change$ 9.88
180 Day Percent Change183.99%
200 Day Price Change$ 8.37
200 Day Percent Change121.66%
Year to Date Price Change$ 8.23
Year to Date Percent Change117.24%

Aerie Pharmaceuticals Inc. (AERI) Key Ratios

PROFITABILITY
EBIT Margin-10.7%
EBITDA Margin-1.2%
Pre-Tax Profit Margin0.0%
Profit Margin Count-20.27%
Gross Margin89.0%
Profit Margin TOT-20.27%
INCOME STATEMENTS
Revenue$ 213,941,000
Revenue Per Share$ 4.3293
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book-4.60
Total Debt To Equity9.40
Int Coverage-1.80
Current Ratio2.30
Leverage Ratio-3.50
Quick Ratio1.80
Long Term Debt To Capital0.90
VALUATION MEASURES
PE Ratio-20.60
Enterprise Value$ 918,137,456
Price to Sales3.5225
Price to Free Cash285.80
PE High Last 5 Years-5.40
Price To Book34.30
Price To Cash Flow100.90
PE Low Last 5 Years-11.10
Price to Tangible Book-4.60
MANAGEMENT EFFECTIVENESS
Receivables Turnover3.30
Invoice Turnover0.70
Assets Turnover0.60
Return Assets-10.85
Return on Equity32.39
Return on Capital-21.84

Aerie Pharmaceuticals Inc. (AERI) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorPricewaterhouseCoopers LLP
CEODavid J. Endicott
Emplyoees376
Last AuditUQ
CIK0001337553
IndustryDrug Manufacturers
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address4301 Emperor Boulevard
Suite 400
Durham, NC 27703
Websitehttps://www.aeriepharma.com
Facsimile-
Telephone+1 919 237-5300
Emailabavishi@aeriepharma.com


Your Recent History
NASDAQ
AERI
Aerie Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.